243 related articles for article (PubMed ID: 37955563)
21. [Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer].
Shu C; Zhu D; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):130-136. PubMed ID: 35224967
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant therapy in non-small cell lung cancer.
Grant C; Hagopian G; Nagasaka M
Crit Rev Oncol Hematol; 2023 Oct; 190():104080. PubMed ID: 37532102
[TBL] [Abstract][Full Text] [Related]
23. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
25. Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges.
D'Aiello A; Stiles B; Ohri N; Levy B; Cohen P; Halmos B
Clin Lung Cancer; 2024 May; 25(3):197-214. PubMed ID: 38462413
[TBL] [Abstract][Full Text] [Related]
26. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
Zhao R; Guan X; Zhang P; Liu Y; Xu Y; Sun C; Qiu S; Zhu W; Yang Z; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):175. PubMed ID: 38573518
[TBL] [Abstract][Full Text] [Related]
27. Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy.
Benitez JC; Remon J; Besse B
Clin Cancer Res; 2020 Oct; 26(19):5068-5077. PubMed ID: 32434852
[TBL] [Abstract][Full Text] [Related]
28. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
Gentzler RD; Riley DO; Martin LW
Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy in Non-small Cell Lung Cancer: a Review.
Sequeira T; Almodovar MT
Port J Card Thorac Vasc Surg; 2023 Oct; 30(3):55-65. PubMed ID: 38499025
[TBL] [Abstract][Full Text] [Related]
30. Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non-small-cell Lung Cancer: A Systematic Review.
Takada K; Takamori S; Brunetti L; Crucitti P; Cortellini A
Clin Lung Cancer; 2023 Nov; 24(7):581-590.e5. PubMed ID: 37741717
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
32. [Research Progress, Benefit Groups, Treatment Cycle and Efficacy Prediction
of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer].
Ji J; Zhang C; Peng L; Jiao W
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):92-101. PubMed ID: 35224962
[TBL] [Abstract][Full Text] [Related]
33. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer.
Zhao Y; Wucherpfennig KW
Curr Opin Oncol; 2024 May; 36(3):136-142. PubMed ID: 38573202
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
36. New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination.
Fernandes MP; Oliveira C; Sousa H; Oliveira J
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835456
[TBL] [Abstract][Full Text] [Related]
37. [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].
Qi C; Tian P; Li W
Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):138-146. PubMed ID: 38453446
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
Zaim R; Redekop K; Uyl-de Groot CA
J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]